CD274 and neoplasm: Such therapeutic decisions are not currently supported by either tumor PD-L1 or TMB status, introducing an unmet clinical need and an opportunity for dynamic assessments of ctDNA to guide treatment selection based on real-time tracking of circulating tumor burden.